Atlas Trials

A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL

Clinical trial NCT05950997 · RECRUITING

Trial details

NCT number
NCT05950997
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia
Start date
2024-04-16
Primary completion
2026-05-31
Enrollment
89

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.